semaglutide fda shortage list FDA's GLP-1 decision kicks off 'unprecedented' tussle over Semaglutide and Tirzepatide No Longer

Ozempic (semaglutide) summary of product characteristics

doi: 10.1177/1049909113494748 7

Severe obesity or type 2 diabetes requiring urgent intervention If a patients body mass index (BMI) is in the severe or morbid obesity range, or if they have uncontrolled type 2 diabetes with high blood sugar levels and/or A1C, waiting for thyroid stabilization could delay needed care

[4] Ballatori N, Krance SM, Notenboom S, et al

On the one hand, metabolic diseases, including high blood pressure, hypertension, and type two diabetes, are critical precursors and risk factors for coronary heart disease

The FDA approved it in 2012 for chronic weight management in adults with a BMI of 30 or greater, or a BMI of 27 or greater with at least one weight-related comorbidity such as high blood pressure, type 2 diabetes, or high cholesterol